
Quickly, I’m going to explain why I’m writing an extra article today….
Someone from our team is moving on from PTT & we’d like to ask you all to support us with a parting bonus! Every $ we make from subscriptions today, will go directly to supporting someone who worked for free, for months, to support a young media platform trying to put Gen Z perspectives into the world. He’s one of the hardest working and admirable people I’ve ever met, and I’d like to give him a big gift that will set him up well for the future!
A $150/year subscription gets you access to all of our paywalled research, which is much more focused and actionable in your work. If you really want to support, consider using the Honorable Reader plan and choosing how much $ you’d like to contribute. Many of our subscribers are purchasing with a company expense budget — it’s very high ROI. Please consider subscribing below and enjoy today’s article. Reminder: every $ from subscriptions that we make today goes toward a parting bonus for one of the hardest working young kids I’ve ever met.
Yesterday, researchers at Columbia University announced they had done something that was technically impossible six months ago: precisely edit human embryos without causing the large-scale chromosomal damage that made earlier CRISPR work too dangerous to consider. The news was delivered without fanfare; they simply issued a preprint. It was a call for public debate. It was the quiet tone of scientists who know they just handed society a problem that is going to be mighty challenging to solve.
But the message was clear, whether researchers wanted to admit it or not: we can now build designer babies. Not safely yet. Not legally. Not ethically. But technically? We’re there. The only thing that is going to stop us in the next ten, twenty, and thirty years from modifying for high intelligence, low disease, and everything else is…ethics.
What Actually Happened
Dieter Egli’s team at Columbia did something elegant: they replaced the genetic scissors of CRISPR with a scalpel. Rather than slicing DNA and hoping for the best, they used “base editing,” a technique that swaps out individual letters in the genetic code without cutting. No cuts means no chromosomal damage. No chromosomal loss means the embryos don’t end up with missing genes that trigger developmental chaos.
The team edited two genes: one linked to cholesterol levels, another to hemoglobin production. These weren’t speculative targets. These are diseases with real suffering. Familial hypercholesterolemia kills people in their 40s and 50s. Sickle cell disease kills people younger. If you could edit an embryo to prevent these, you would be preventing immense suffering.
But here’s the catch, and bioethicists have been waiting for this moment for thirty years: the moment you can safely edit disease out of embryos is the moment you can safely edit anything out. Or in.
The Problem Isn’t Technical Anymore
The lead researchers—Egli especially—understand the weight of what they’ve done. Their tone throughout the announcements is almost apologetic. “We need public debate,” Egli said. “The work is nowhere near clinic-ready.” This is the language of scientists who are about to lose control of their research to markets and politics.
But this caution misses the actual problem. The problem was never “can we do this safely.” The problem was always “can we keep people from doing this unsafely once they know it’s possible.”
And the answer is no. Not really.
Hank Greely, biomedicist at Stanford, said: “You could set up an IVF lab and a genetic testing lab for probably a handful of millions of dollars and start doing this.” A handful of millions. That’s the budget of a moderately successful venture capital fund. This means that anyone who is willing to compromise on their ethics can build this, and anyone who is willing to handle the guilt could be a customer. Or is this actually something to be guilty about? I’m not sure I have the answer.
The moment someone has the capability and a financial incentive the question shifts from “should we?” to “how do we regulate who and when?”
Why This Changes Everything (And Nothing)
The Columbia breakthrough is genuinely important technically. Base editing is cleaner, safer, more precise. It reduces the risk profile from “probably creates really sick kids” to “creates mostly healthy kids, sometimes with surprising issues.” That’s a real move in the direction of viability.
But ethically? It changes nothing.
The line bioethicists drew has never moved. The World Health Organization was clear in 2019: heritable human germline editing is irresponsible. Not because it’s too risky but because it’s too powerful, and power matters.
Here’s what Greely and others understood that the general public hasn’t quite grasped yet: this isn’t about preventing disease. Not really. Once you can edit diseases, the economic incentive flips. The question becomes: why would anyone choose a naturally-conceived child over an edited one, if they could afford it?
And they would be right to ask. If you can reduce your child’s risk of heart disease, Alzheimer’s, diabetes, cancer—if you can increase their height, their immune function, their metabolic efficiency—the calculation changes. Not for everyone. But for everyone who can afford it. And IVF plus gene editing, once it’s established and safe, probably costs what a Tesla costs. Maybe less eventually.
The Economic Game That’s About to Start
Here’s what happens next. Not immediately. But within three to five years.
First, wealthy individuals—particularly in places with less stringent regulation (Singapore, possibly some jurisdictions in the UAE, potentially parts of Eastern Europe)—will begin using base editing to edit embryos. Quietly at first. Then openly as the first cohorts of edited children reach age 5 or 10 and appear healthy, and high-functioning. The visible safety data will be used as a bludgeon against regulators.
Second, competition will emerge. Some clinic will offer “comprehensive health optimization” (editing for risk factors) as a boutique service. It will market on a simple truth: we’re making your children healthier. That’s not a lie. It’s also not the whole story. But it doesn’t need to be.
Third, the market will split. Affluent countries with tight regulation will resist. Poor and middle-income countries will embrace it, because the incentives align differently when you’re not wealthy enough to avoid other risks. And the global North will face a choice: either regulate ourselves into irrelevance while the gene-edited children of China, India, and the Gulf start showing observable advantages, or we accept a world where genetic enhancement is standard for people with capital.
Fourth, insurance companies will get involved. Not explicitly. But insurers will notice that edited embryos have better health outcomes. Genetic screening will become routine for IVF. And then uninsured or underinsured pregnancies will face higher premiums. Because they’re statistically riskier. The genetic lottery is riskier and that’s just actuary math.
The Trap We’re Walking Into
This is where the ethics actually matter, and why the Columbia team’s call for “public debate” sounds almost quaint.
Public debate assumes that the outcome of debate will affect what happens. It won’t. The reason is simple: once the technology exists, the incentive structure shifts. You can debate whether designer babies are right or wrong until the heat death of the universe, but a parent who could edit their child’s genome—removing a devastating disease, improving their health profile—and chooses not to, will have to explain to their child someday why. That’s psychologically untenable. Once the option exists, it’s no longer optional.
This is different from previous ethical lines in medicine. It’s not like deciding whether to pursue expensive cancer treatment—that’s about extending life for someone who exists. This is about creating a different person, one with different capabilities, different health outcomes, different potential. And once one cohort has those advantages, the next cohort is disadvantaged by comparison.
The philosophers call this a “prisoner’s dilemma of the genome.” Everyone would be better off if no one edited. But if everyone else is editing, then not editing your child is itself a choice with consequences.
The result: genetic enhancement becomes mandatory for anyone who can afford it, not because they think it’s right, but because not doing it puts their child at a disadvantage. This isn’t some abstract sci-fi world, but rather, it’s a real game theory problem with the potential to change the world as we know it.
The Political Game
Governments understand this at some level. That’s why the WHO took a strong stance. That’s why most wealthy countries have embryo editing restrictions. But restrictions only work if they’re enforced, and enforcement requires:
Monopoly on IVF services (hard in a globalized world where travel is cheap)
Genetic testing bans (impossible—testing gets cheaper every year)
International coordination (we can barely coordinate on carbon)
Public acceptance (weakening as the first cohort of edited children appears healthy and smart)
What will actually happen is a race to the bottom, dressed up as regulation. Countries will claim they’re restricting designer babies while quietly permitting “therapeutic editing.” The line between therapeutic and enhancement is about as real as the line between “research” and “experimental treatment.” It’s wherever you draw it.
Some countries will lean into it. Singapore is explicitly planning to become a global hub for genomic medicine. The Gulf is investing heavily. China has already run embryo editing experiments (and faced international backlash). The US will waffle, then eventually split—some states permitting it, others banning it, international capital flowing to whoever permits it.
The end state looks like this: genetic enhancement is legal and available in most of the world, regulated in some places but effectively unregulated in the places that matter financially. It becomes standard for the global elite, aspirational for the upper-middle class, impossible for everyone else. Over generations, you get a genetic class system. There are, actually, interesting parallels to be drawn between genetic editing and abortion; don’t take that as me making some kind of argument, just a note about how medical technology that improve health outcomes on paper often receive some form of dissent from those who believe in the “soul.” Christian Evangelicals still hate IVF.
What the Science Actually Shows
One thing worth noting: even if the Columbia team’s editing worked perfectly, even if there were zero off-target effects and zero mosaicism, we still don’t know most of what matters.
Height? Probably genetic, but environmental factors matter enormously.
Intelligence? Heritability is 40–60%, and most of it seems to be highly polygenic (lots of genes, each with small effects). Editing for IQ is like tuning a thousand knobs, each of which might affect something else entirely.
Disease resistance? More tractable. Sickle cell resistance? Doable. Broad disease resistance? Probably not yet.
The science will improve. We’ll get better at understanding which genes matter, which combinations matter, what the downstream effects are. Within twenty years, we’ll probably be pretty good at eliminating serious genetic diseases. We might even be decent at modest health enhancements.
But the political and economic game isn’t being played in the lab. It’s being played in boardrooms, investment funds, policy meetings, and the calculations of parents trying to do right by their children.
The Future We’re Actually Heading Toward
The reasonable timeline:
Now–2030: Edited embryos used in private clinics, mostly in Asia and the Gulf. First generation reaches adolescence, appears mostly healthy. Regulatory agencies around the world fumble their response. Some Western countries quietly permit “research” on edited embryos. Investment pours in.
2030–2035: Second-generation editing addresses more complex traits—disease risk factors, moderate enhancements. Market normalizes. China and Singapore have thousands of edited children entering schools. IQ differences start showing up in aggregate data. Western countries begin to fracture—some banning it, others permitting it, still others pretending not to notice.
2035–2045: Editing becomes routine for wealthy parents. Genetic enhancement is normal at certain income levels. Insurance markets adapt. Genetic screening becomes mandatory for many reproductive decisions. Middle class begins to split—those who can afford editing, those who can’t.
2045+: Two genetic populations, increasingly diverged. Genetic enhancement is treated like education—something the wealthy invest in, the poor can’t afford, and governments slowly stop trying to regulate because regulation failed and everyone knows it.
What Actually Happens to Ethics in This World
Here’s the part that gets left out of bioethics discussions: once something becomes normal, it becomes moral.
Slavery was normal. Driving cars that release carbon was normal. Antibiotic overuse was normal. In each case, the initial ethical objections got worn down by normalization and economic incentives. A generation grows up in the new world not questioning it.
That will happen here. Your children will find the ethical hand-wringing about designer babies quaint. “Why would you not edit out genetic disease if you could?” they’ll ask, confused. “That’s like not vaccinating.”
The only way this doesn’t happen is if the technology actually gets restricted globally, and there’s no credible path to that. The incentives are too strong, the enforcement mechanisms too weak, the economic gains too large.
What This Means for You (If You Have Capital)
If you’re in the class of people who can afford this, you’re going to face a choice in the next five to fifteen years: edit your embryos or don’t.
The economic logic will push you toward doing it. The health benefits are real. The insurance logic is getting clearer. And once some fraction of the wealthy are doing it, not doing it puts your children at a disadvantage.
You’ll probably rationalize it. “We’re just fixing disease.” “We’re not enhancing, just protecting.” “We’d be irresponsible not to.” These rationalizations will be mostly true and somewhat dishonest in a way you’ll have learned not to examine too closely.
If you’re not in that class, you have a different problem: you’ll be living in a world that was designed by and for genetically optimized people, made by parents with more capital than you have.
The Columbia breakthrough is being celebrated as a scientific achievement. It is. It’s genuinely elegant science, and Egli is a serious researcher doing serious work.
But what it actually represents is the moment when genetic inequality shifted from being a thing we discuss to being a thing we demonstrate and act on.
Regulation will fail. Not because regulators are stupid, but because the incentive structures are too powerful and the technology too distributed. The best we can hope for is slower adoption and slightly more international coordination than seems possible.
The Columbia team called for public debate and that’s valorous, but the real conversation isn’t happening in academic papers or bioethics committees. It’s happening in venture capital funds, insurance companies, and government agencies.
The answer they’re reaching is the same one Egli reached: if you can do it safely, and other people are doing it, you probably will.
The future isn’t something that happens to us. It’s something we build by making small decisions that compound. And we just moved the needle very far toward a world where genetic inequality is engineered from conception.
Thank you for reading and please consider supporting our employee by subscribing today for $150/year!
Thanks folks & stay curious.
—J&E